IDXX logo

IDEXX LABORATORIES INC

IDXXNASDAQ
πŸ† #350 by market capEarnings Nov 2US Equity
$533.99β–² $4.97 (+0.93%)
Live
πŸ””
Track IDXX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.9%
7dβ–² 2.4%
14dβ–² 4.6%
30dβ–Ό 3.8%
ytdβ–Ό 21.1%
1yβ–Ό 15.3%
🏦Market Cap
$42.12B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+10.4%
Healthy
πŸ“ŠGross Margin
62.5%
High
πŸ’΅FCF Margin
27.5%
Strong
βš–οΈP/S Ratio
9.2x
Elevated
Otter Score
96
Very Good

Trading Snapshot

Day Range
$526.58 – $537.36
52-Week Range
$500.61 – $769.98
Volume
$3.69B
Avg Volume
$3.56B
Shares Outstanding
78.9M
Next Earnings
Nov 10, 2026

Fundamentals Snapshot

Annual Revenue
$4.30B
Last Q Revenue
$1.22B
P/E Ratio
37.2
P/S Ratio
9.2x
EPS (TTM)
$14.23
Dividend Yield
0.00%
Dilution (1yr)
βˆ’2.3%

Why Investors Own IDXX

  • βœ“High-growth profile β€” revenue up +46.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 75% gross margin and 15% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IDXX logo

IDEXX LABORATORIES INC

IDXX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.3Bβ–² +10.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.8%β–² +1.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.4Bβ–² +20.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.1Bβ–² +32.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
80.7Mβ–Ό βˆ’2.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$897Mβ–Ό βˆ’$198M YoY
StockOtter Β· stockotter.space

About IDEXX LABORATORIES INC

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
96/100

Analyst Price Target

β“˜
Average Target
$656.41
β–² +22.9% Upside
High Target$803.07
Low Target$547.25
Based on 14 analysts

Latest News & Updates

Zacks Investment ResearchΒ·6d ago

Should You Continue to Hold IDXX Stock in Your Portfolio?

IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.

Defense WorldΒ·8d ago

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

IDEXX Laboratories (NASDAQ: IDXX) executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while rea

Defense WorldΒ·8d ago

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

IDEXX Laboratories (NASDAQ: IDXX) executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercia

Zacks Investment ResearchΒ·12d ago

IDEXX Stock Gains Following the Acquisition of CoVet

IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.

Business WireΒ·12d ago

IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dxβ„’ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.

Business WireΒ·13d ago

IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.